Pharmacovigilance Career in India: PvPI, Drug Safety Roles and Skills You Need

Every medicine carries some risk, and many side effects only become visible once a drug is used by millions of people. Pharmacovigilance (PV) is the science of finding, assessing and preventing those adverse effects. For pharmacy, life sciences and medical graduates in India, it has become one of the most accessible ways into the pharmaceutical industry.

This guide covers how pharmacovigilance works in India, the roles available, the tools and skills employers expect, and how to get started.

What is pharmacovigilance?

The World Health Organization defines pharmacovigilance as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem. In practice, PV teams collect adverse event reports, evaluate them, report them to regulators within strict timelines, and look for patterns (signals) that could change how a medicine is used.

Pharmacovigilance in India: PvPI and the regulators

• Pharmacovigilance Programme of India (PvPI): launched by the Ministry of Health and Family Welfare in July 2010. Since April 2011 its National Coordination Centre has been the Indian Pharmacopoeia Commission (IPC) in Ghaziabad.
• ADR Monitoring Centres (AMCs): a nationwide network of centres, mostly in medical colleges and hospitals, collects adverse drug reaction reports and forwards them to the NCC.
• Reporting by anyone: healthcare professionals and patients can report suspected adverse reactions through the PvPI form, mobile app or the toll-free helpline 1800-180-3024.
• Global recognition: in October 2017, the PvPI National Coordination Centre at IPC was designated a WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services.
• Industry obligations: CDSCO requires companies holding marketing authorisations to run a pharmacovigilance system, report serious adverse events and submit periodic safety update reports (PSURs) for new drugs.

Pharmacovigilance roles explained

Drug Safety Associate / Case Processing Associate

The most common entry role. You receive individual case safety reports (ICSRs) from literature, spontaneous reports, clinical trials or patient programmes; check validity; enter data in the safety database; code events and drugs using MedDRA and WHODrug; and write a clear case narrative.

Quality reviewer and senior associate

Reviews processed cases for accuracy, consistency and regulatory compliance, and mentors new associates.

Medical reviewer

Usually a medically qualified professional who assesses seriousness, expectedness and causality for complex cases.

Aggregate reports and signal management

Scientists and writers prepare periodic reports such as PSURs/PBRERs and DSURs, and analyse safety data to detect and evaluate signals.

PV systems, compliance and QPPV support

Experienced professionals manage safety databases, audits, SOPs and the overall PV system for a company.

Tools and skills employers expect

• Understanding of ICSR processing: minimum criteria, seriousness, expectedness and causality
• MedDRA coding and WHODrug dictionary basics
• Familiarity with safety database concepts (commercial systems such as Oracle Argus, ArisGlobal LifeSphere or Veeva Vault Safety are widely used)
• Regulatory timelines for expedited reporting and periodic reports
• Clear medical writing for case narratives
• Pharmacology and disease knowledge, plus attention to detail

How AI is changing drug safety

Automation and AI are now used for case intake, duplicate detection, literature screening and signal detection. Rather than replacing PV professionals, this is shifting the job towards review, judgement and oversight. The CIOMS Working Group XIV report sets out principles for using AI responsibly in pharmacovigilance; we explain them in AI in Pharmacovigilance: CIOMS WG XIV Principles Explained.

Who can apply, and where the jobs are

B.Pharm, M.Pharm, Pharm.D, life sciences, biotechnology and microbiology graduates, as well as MBBS, BDS, BHMS and BAMS graduates, are regularly hired into drug safety teams. Employers include pharmaceutical companies, CROs and specialist PV service providers, with large teams in cities such as Bengaluru, Hyderabad, Mumbai, Pune, Chennai and Delhi NCR. Because the work is database- and document-based, many roles are hybrid or remote.

A practical plan to get started

1. Strengthen your pharmacology basics and learn the ICSR workflow end to end.
2. Practise MedDRA coding and writing case narratives from sample cases.
3. Learn how PvPI, CDSCO and global regulators expect adverse events to be reported.
4. Prepare for interviews with questions on seriousness criteria, causality and reporting timelines.
5. Build a wider base in clinical trials, since many PV roles also handle trial safety data.

Key takeaways

• Pharmacovigilance protects patients by detecting and preventing adverse drug effects.
• In India, PvPI (coordinated by IPC Ghaziabad) and CDSCO set the framework.
• Drug Safety Associate is the main entry role; MedDRA, ICSR processing and narrative writing are core skills.
• AI is changing the work towards review and oversight, not removing the need for trained people.

Learn pharmacovigilance online with CliniXen

CliniXen Institute's 6-month online Advanced PG Diploma in Clinical Research & Pharmacovigilance covers ICSR processing, MedDRA coding, signal management, PvPI and AI in drug safety, and is open to learners across India. Also read our clinical research career guide for India.

References

1. Pharmacovigilance Programme of India (PvPI), Indian Pharmacopoeia Commission. https://ipc.gov.in/PvPI/about.html
2. WHO India: WHO Collaborating Centre for Pharmacovigilance in Public Health Programmes and Regulatory Services launched (2017). https://www.who.int/india/news/item/02-11-2017-who-collaborating-centre-for-pharmacovigilance-in-public-health-programmes-and-regulatory-services-in-india-launched
3. World Health Organization: Pharmacovigilance. https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance

Disclaimer: This article is for educational purposes and reflects publicly available regulatory and scientific information at the time of writing. Guidance documents are updated periodically; always consult the latest official version.